ARISTOTLE® is a blood test that can detect the molecular signatures of multiple cancers from a single sample of blood to help find cancer earlier. ARISTOTLE® can discretely detect each cancer signature with high sensitivity and specificity. (1)
|
|
Early Cancer Detection Matters!
|
Everyone knows someone with Cancer. Unfortunately, almost 50% of people are diagnosed in the later stages when outcomes are poor(2). A late stage cancer diagnosis can be attributed to many factors such as postponing cancer screening, the fact that symptoms often don't appear until cancer has progressed, or a lack of convenient screening options.
Aristotle® is a multi-cancer test panel that uses mRNA technology to simultaneously detect multiple cancer signatures from a single sample of blood. Aristotle looks for the following cancer signatures:
|
|
The Benefits of Early Cancer Detection
|
The average cost of late-stage cancer diagnosis is almost 2-3 times the cost of an early-stage diagnosis (3). Finding cancer earlier reduces costs.
|
Survival rates dramatically improve when cancer is found in the early stages. (2)
|
Our Science
|
Our underlying mRNA technology, The Sentinel Principle, has been validated in more than 9,000 patients and used by more than 100,000 patients in North America. (1) Aristotle was selected for online publication at the 2020 annual meeting of the American Society of Clinical Oncology (ASCO).
Our laboratory in Richmond, VA is certified according to the Clinical Laboratory Improvement Amendment (CLIA) for high complexity laboratory testing through the Centers of Medicare and Medicaid Services (CMS). In addition, the lab is accredited through the College of American Pathologists (CAP). These certifications demonstrate our highest commitment to excellence in laboratory test processing and our passion for patient care.
|
|
Sources:
1. Aristotle: A single blood test for pan-cancer screening. Dempsey AA, Chao S, Stamatiou D, Pilcz T, Ying J, and Burakoff R; Journal of Clinical Oncology 2020; 38:15_suppl, e15037-e15037
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
3. McGarvey, N., Gitlin, M., Fadli, E. et al. Increased healthcare costs by later stage cancer diagnosis. BMC Health Serv Res 22, 1155 (2022). https://doi.org/10.1186/s12913-022-08457-6
Aristotle® was developed and its performance characteristics determined by Stage Zero Life Sciences, Inc. It has not been cleared or approved by the US Food and Drug Administration. This test is performed in a CLIA certified laboratory and is intended for clinical purposes. The ARISTOTLE® test must be ordered by and used only in consultation with a healthcare provider.
1. Aristotle: A single blood test for pan-cancer screening. Dempsey AA, Chao S, Stamatiou D, Pilcz T, Ying J, and Burakoff R; Journal of Clinical Oncology 2020; 38:15_suppl, e15037-e15037
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
3. McGarvey, N., Gitlin, M., Fadli, E. et al. Increased healthcare costs by later stage cancer diagnosis. BMC Health Serv Res 22, 1155 (2022). https://doi.org/10.1186/s12913-022-08457-6
Aristotle® was developed and its performance characteristics determined by Stage Zero Life Sciences, Inc. It has not been cleared or approved by the US Food and Drug Administration. This test is performed in a CLIA certified laboratory and is intended for clinical purposes. The ARISTOTLE® test must be ordered by and used only in consultation with a healthcare provider.
